Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) EBIT (2016 - 2025)

Iradimed (IRMD) has disclosed EBIT for 13 consecutive years, with -$13.1 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 325.79% to -$13.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, down 72.88% year-over-year, with the annual reading at $6.0 million for FY2025, 72.88% down from the prior year.
  • EBIT for Q4 2025 was -$13.1 million at Iradimed, down from $6.8 million in the prior quarter.
  • The five-year high for EBIT was $6.8 million in Q3 2025, with the low at -$13.1 million in Q4 2025.
  • Average EBIT over 5 years is $3.7 million, with a median of $4.5 million recorded in 2022.
  • The sharpest move saw EBIT soared 377.64% in 2021, then tumbled 325.79% in 2025.
  • Over 5 years, EBIT stood at $3.1 million in 2021, then skyrocketed by 36.8% to $4.3 million in 2022, then rose by 21.3% to $5.2 million in 2023, then grew by 12.42% to $5.8 million in 2024, then plummeted by 325.79% to -$13.1 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$13.1 million, $6.8 million, and $6.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.